Levi Strauss & Co. vs Zoetis Inc — how do they compare? Levi Strauss & Co. trades at $24.41 (market cap $9.21B), while Zoetis Inc trades at $74.86 (market cap $31.95B). The key difference: Zoetis Inc is far larger — about 3.5× Levi Strauss & Co.'s market cap, and Zoetis Inc pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| LEVI | ZTS | |
|---|---|---|
Market Cap | $9.21B | $31.95B |
Sector | Consumer Cyclical | Health |
52-Week High | $24.99 | $156.76 |
52-Week Low | $17.92 | $71.91 |
Enterprise Value | $10.52B | $39.24B |
Dividend Yield | 2.68% | 2.78% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zoetis (ZTS) trades at $76.05, down 0.67% on the day, with a neutral technical signal and bearish moving averages. The company maintains strong fundamentals with a 28.03% net income margin and 67.75% ROE, though Q1 2026 earnings missed expectations. Recent news highlights multiple securities class action lawsuits filed against the company, creating near-term uncertainty despite the launch of new product Lenivia in Canada and EU markets.
The stock presents a mixed outlook with attractive valuation metrics (P/E 12.55) and analyst consensus price target of $101.43 suggesting 33% upside potential. However, legal challenges and the recent earnings miss pose significant near-term risks. Institutional sentiment remains divided with 47% buy ratings versus 53% hold ratings, indicating cautious optimism amid legal headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →